Arrowhead Pharmaceuticals announced successful topline results from its Phase 3 SHASTA-3 and SHASTA-4 trials for plozasiran, demonstrating significant reductions in triglyceride levels and acute pancreatitis occurrences in patients with severe hypertriglyceridemia. This positive data positions the drug for a supplemental new drug application to the FDA, potentially expanding its market significantly beyond its current familial chylomicronemia syndrome indication.
Arrowhead Pharmaceuticals (ARWR) released highly positive Phase 3 trial results for plozasiran, showing substantial efficacy in reducing triglycerides and acute pancreatitis in severe hypertriglyceridemia patients. This is a major catalyst for ARWR as it significantly broadens the potential market for plozasiran, which is currently approved only for familial chylomicronemia syndrome. The strong data, including a favorable safety profile and plans for a supplemental NDA by late 2026, suggest a significant long-term revenue opportunity for the company. Traders should note the immediate positive stock reaction and consider the long-term growth potential if regulatory approvals are secured.